Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherNEUROPHARMACOLOGY

GR196429: A Nonindolic Agonist at High-Affinity Melatonin Receptors

Isabel J. M. Beresford, Christopher Browning, Sarah J. Starkey, Jason Brown, Steven M. Foord, Josephine Coughlan, Peter C. North, Margarita L. Dubocovich and Russell M. Hagan
Journal of Pharmacology and Experimental Therapeutics June 1998, 285 (3) 1239-1245;
Isabel J. M. Beresford
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Browning
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah J. Starkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jason Brown
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven M. Foord
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Josephine Coughlan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter C. North
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Margarita L. Dubocovich
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Russell M. Hagan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

N-[2-[2,3,7,8-tetrahydro-1H-furo(2,3-g)indol-1-yl]ethyl]acetamide (GR196429) is a novel, nonindolic melatonin receptor agonist. GR196429 had high affinity for human mt1 (pKi 9.9) and MT2 (pKi 9.8) receptors expressed in Chinese hamster ovary cells and for 2-[125I]-iodomelatonin binding sites in human cerebellum, guinea pig superior colliculus and hypothalamus and chicken retina and tectum (pKi 8.8–9.5). GR196429 was inactive at a wide range of other hormone and neurotransmitter receptors. In Chinese hamster ovary cells expressing human mt1 or MT2 receptors, both melatonin and GR196429 dose-dependently inhibited forskolin-stimulated cAMP accumulation. In rabbit isolated retina, GR196429 inhibited calcium-dependent [3H]-dopamine release with potency (IC50 30 pM) and maximum effect (76 ± 5% at 1 nM) similar to those of melatonin. The response was antagonized by the melatonin receptor antagonist luzindole (1 μM). In slices of rat brain suprachiasmatic nucleus, perfusion (1 h) with GR196429 at zeitgeber time 10 phase advanced the circadian peak in neuronal activity measured on the following day, with a maximum phase advance of 2.7 ± 0.3 h at 10 pM and an EC50 of 0.6 pM, results that indicated a melatonin-like action on the phase of the circadian clock. CNS penetration and duration of receptor occupancy was determined in anex vivo radioligand binding assay. In membranes of guinea pig superior colliculus prepared 30 min after administration of GR196429 (s.c.), 2-[125I]-iodomelatonin binding was inhibited with an ED50 of 0.04 mg/kg. After a dose of 1 mg/kg, binding was significantly inhibited for at least 3 h. Thus GR196429 is a potent and selective agonist at high-affinity melatonin receptors, which modulates circadian rhythms in an in vitromodel of the circadian clock and which readily penetrates the CNS.

Footnotes

  • Send reprint requests to: Dr. Russell Hagan, Neurosciences, Glaxo Wellcome Research and Development Ltd., Glaxo Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK.

  • ↵1 The nomenclature and classification of melatonin receptors used here was approved recently by the Nomenclature Committee of the International Union of Pharmacology (Dubocovich et al., 1998). The denomination “mt1” corresponds to that of the recombinant receptors previously termed Mel1A. MT2 refers to native receptors with pharmacological characteristics similar to that of the recombinant receptor mt2, previously termed Mel1B. MT3corresponds to the pharmacologically defined melatonin receptor subtype, with unknown molecular structure, previously referred to as ML2.

  • ↵2 Present address: Department of Molecular Pharmacology and Biological Chemistry, 303 East Chicago Avenue, Chicago, IL 60611.

  • Abbreviations:
    ACSF
    artificial cerebrospinal fluid
    CHO
    Chinese hamster ovary
    SCN
    suprachiasmatic nuclei
    ZT
    zeitgeber time
    GR196429
    N-[2-[2,3,7,8-tetrahydro-1H-furo(2,3-g)indol-l-yl]ethyl]acetamide
    • Received September 29, 1997.
    • Accepted February 9, 1998.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 285, Issue 3
1 Jun 1998
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
GR196429: A Nonindolic Agonist at High-Affinity Melatonin Receptors
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherNEUROPHARMACOLOGY

GR196429: A Nonindolic Agonist at High-Affinity Melatonin Receptors

Isabel J. M. Beresford, Christopher Browning, Sarah J. Starkey, Jason Brown, Steven M. Foord, Josephine Coughlan, Peter C. North, Margarita L. Dubocovich and Russell M. Hagan
Journal of Pharmacology and Experimental Therapeutics June 1, 1998, 285 (3) 1239-1245;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherNEUROPHARMACOLOGY

GR196429: A Nonindolic Agonist at High-Affinity Melatonin Receptors

Isabel J. M. Beresford, Christopher Browning, Sarah J. Starkey, Jason Brown, Steven M. Foord, Josephine Coughlan, Peter C. North, Margarita L. Dubocovich and Russell M. Hagan
Journal of Pharmacology and Experimental Therapeutics June 1, 1998, 285 (3) 1239-1245;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Glycine receptor modulation using monoclonal antibodies
  • Iclepertin (BI 425809) in Schizophrenia-Related Models
  • D1 Agonist Versus Methylphenidate on PFC Working Memory
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics